276 related articles for article (PubMed ID: 16205037)
21. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Gupta A; Unadkat JD; Mao Q
J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
[TBL] [Abstract][Full Text] [Related]
22. Conazoles.
Heeres J; Meerpoel L; Lewi P
Molecules; 2010 Jun; 15(6):4129-88. PubMed ID: 20657432
[TBL] [Abstract][Full Text] [Related]
23. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Skóra M; Bulanda M; Jagielski T
Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
[TBL] [Abstract][Full Text] [Related]
25. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
26. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R
Xenobiotica; 2012 May; 42(5):409-16. PubMed ID: 22106961
[TBL] [Abstract][Full Text] [Related]
27. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
29. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
30. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
31. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
32. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
33. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
34. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
35. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
36. Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8.
Niwa T; Imagawa Y
J Pharm Pharm Sci; 2016; 19(4):423-429. PubMed ID: 28057172
[TBL] [Abstract][Full Text] [Related]
37. Advances in antifungal therapy.
Pannaraj PS; Walsh TJ; Baker CJ
Pediatr Infect Dis J; 2005 Oct; 24(10):921-2. PubMed ID: 16220093
[No Abstract] [Full Text] [Related]
38. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
40. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles.
Yamazaki H; Nakamoto M; Shimizu M; Murayama N; Niwa T
Br J Clin Pharmacol; 2010 Jun; 69(6):593-7. PubMed ID: 20565450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
